Well done for finding this information.
Note the reported cost per dose of between $A50 to $A125. Way above what we had understood that Governments had previously been asked to pay.
Even if BTA share of this order was 20%, would be some A$10 million in royalty payments for BTA.
It does seem apparent that GSK is now out in the marketplace selling Relenza to Governments around the world.